New drug combo aims to tame Tough-to-Treat blood cancer
NCT ID NCT03763162
Summary
This study is testing a two-part drug combination to control multiple myeloma, a blood cancer, in patients whose disease has come back or stopped responding to prior treatments. It combines an immunotherapy drug that helps the immune system attack cancer with other drugs that block cancer cell growth. The main goal is to see how long patients live without their cancer getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT PLASMA CELL MYELOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.